Related Experiment Video
Updated: Aug 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection
Sabina Davidsson1, Anna Messing Eriksson1, Ruzan Udumyan2
1Department of Urology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden.
Background:
Androgens may play a role in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and host responses as the virus is dependent on the androgen-regulated protein transmembrane serine protease 2 for cell entry. Studies have indicated that prostate cancer patients receiving androgen deprivation therapy (ADT) are at reduced risk of SARS-CoV-2 infection and serious complications compared with patients without ADT, but data are inconsistent.
Methods:
A total of 655 prostate cancer patients who were under surveillance at two urology departments in Sweden on April 1, 2020 were included in the study as well as 240 patients with benign prostatic hyperplasia (BPH). At follow-up early in 2021, the participants completed a questionnaire containing information about symptoms compatible with coronavirus disease 2019 (COVID-19). Blood samples were also collected for the assessment of SARS-CoV-2 IgG antibodies (SARS-CoV-2 Total; Siemens). We used multivariable logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between ADT and the risk of SARS-CoV-2 infection.
Results:
The cumulative incidence of SARS-CoV-2 seropositivity was 13.4% among patients receiving ADT and 10.4% among patients without ADT. After adjusting for potential confounders, we observed no differences in symptoms or risk of SARS-CoV-2 infection between patients with and without ADT (OR: 0.98; 95% CI: 0.52-1.85). Higher body mass index, Type 1 diabetes, and prostate cancer severity, defined by high Gleason score (8-10; OR: 2.06; 95% CI: 1.04-4.09) or elevated levels of prostate-specific antigen (>20 µg/l; OR: 2.15; 95% CI: 1.13-4.07) were associated with increased risk of SARS-CoV-2 infection. Overall, the risk of SARS-CoV-2 infection was not higher among men with prostate cancer than among men with BPH.
Conclusions:
Our results do not support the hypothesis that ADT use in prostate cancer patients reduces the risk or symptom severity of SARS-CoV-2 infection or that prostate cancer patients are at increased risk of COVID-19 compared with men without prostate cancer.
Insights
Androgen deprivation therapy (ADT) in prostate cancer patients did not reduce SARS-CoV-2 infection risk. Prostate cancer patients were not at higher risk for COVID-19 compared to benign prostatic hyperplasia patients.
Area of Science:
- Oncology
- Infectious Diseases
- Virology
Background:
- Androgens may influence SARS-CoV-2 infection due to the virus's dependence on androgen-regulated TMPRSS2 for cell entry.
- Prior studies suggested androgen deprivation therapy (ADT) might lower SARS-CoV-2 infection risk in prostate cancer patients, but findings were inconsistent.
Purpose of the Study:
- To investigate the association between ADT and the risk of SARS-CoV-2 infection and COVID-19 severity in prostate cancer patients.
- To compare SARS-CoV-2 infection risk between prostate cancer patients and those with benign prostatic hyperplasia (BPH).
Main Methods:
- A cohort study included 655 prostate cancer patients and 240 BPH patients in Sweden.
- Participants completed questionnaires on COVID-19 symptoms and provided blood samples for SARS-CoV-2 IgG antibody testing.
- Multivariable logistic regression models were used to analyze the association between ADT and SARS-CoV-2 infection risk.
Main Results:
- The cumulative incidence of SARS-CoV-2 seropositivity was 13.4% for ADT users and 10.4% for non-users.
- Adjusted analysis revealed no significant difference in SARS-CoV-2 infection risk or symptoms between ADT users and non-users (OR: 0.98; 95% CI: 0.52-1.85).
- Higher BMI, Type 1 diabetes, and prostate cancer severity (Gleason score 8-10 or PSA >20 µg/l) were associated with increased SARS-CoV-2 infection risk.
Conclusions:
- The study findings do not support the hypothesis that ADT reduces SARS-CoV-2 infection risk or severity in prostate cancer patients.
- Prostate cancer patients did not exhibit a higher risk of COVID-19 compared to men with BPH.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Infertility in Males
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Psychoneuroimmunology: Diabetes and Cancer

